Zobrazeno 1 - 10
of 17
pro vyhledávání: '"George Kemble"'
Autor:
Peter Schmid, Kathleen N. Moore, Andrew Brenner, Arthur E. Frankel, Gerald Steven Falchook, H. A. Burris, Katharine Grimmer, Juanita Lopez, George Kemble, EM Dean, J. R. Infante, William McCulloch, Erkut Borazanci, Steven J.M. Jones, Manish R. Patel, H.-T. Arkenau
Publikováno v:
Cancer Research. 77:P6-11
Introduction FASN inhibition is a novel approach to cancer treatment involving selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first-in-class, small molecule reversible inhibitor of FASN t
Publikováno v:
Cancer Research. 79:3723-3723
Pancreatic cancer is the fourth leading cause of cancer related deaths in the United States and continues to be hindered with limited treatment options. One of the current therapeutic regimens for pancreatic cancer often include the nucleoside analog
Publikováno v:
Cancer Research. 79:708-708
Fatty acid synthase (FASN) is a novel therapeutic target for cancer as it has increased expression in many different types of cancers. There has been significant understanding that cancer cells can hijack and modify tightly regulated metabolic pathwa
Autor:
Anh-Thu Le, Brent J. Hallahan, Eun Lee, B. Mark Evers, Timothy S. Heuer, Andrew N. Lane, Piotr G. Rychahou, Tianyan Gao, Sally E. Hodges, Manjula Sunkara, Teresa W.-M. Fan, Timothy L. Scott, Andrew D. Morris, Jinpeng Liu, Ji Tae Kim, Sivakumaran Theru Arumugam, Chi Wang, George Kemble, Hunter N. B. Moseley, Jennifer W. Harris, Dana Napier, Robert M. Flight, Heidi L. Weiss, Yekaterina Y. Zaytseva
Publikováno v:
Cancer Research. 77:452-452
Fatty Acid Synthase (FASN), a key enzyme of de novo lipogenesis, is upregulated in many cancers including colorectal cancer (CRC); increased FASN expression is associated with poor prognosis. Potent FASN inhibitors developed by 3-V Biosciences demons
Autor:
Arthur E. Frankel, George Kemble, Peter Schmid, Howard A. Burris, Gerald Steven Falchook, Manish R. Patel, Hendrik-Tobias Arkenau, Kathleen N. Moore, Jeffrey R. Infante, Andrew Brenner, Suzanne F. Jones, William McCulloch, Juanita Lopez, Erkut Borazanci, Emma Dean
Publikováno v:
Cancer Research. 77:CT153-CT153
Introduction FASN inhibition causes selective disruption of palmitate biosynthesis that, in tumor cells, leads to apoptosis. TVB-2640 is an oral, first-in-class, small molecule reversible inhibitor of FASN that demonstrated in vivo antitumor effects.
Autor:
Joanna Waszczuk, Marina Fridlib, Doug Buckley, William McCulloch, Richard Crowley, Marie O'Farrell, Claudia Rubio, Katharine Grimmer, Julie Lai, George Kemble, Richard Benn Abegania Ventura, Tim Heuer
Publikováno v:
Cancer Research. 76:LB-214
TVB-2640 is an oral, first-in-class, selective and reversible inhibitor of fatty acid synthase (FASN) in Phase 1 testing in solid tumor patients (study 3V2640-CLIN-002). FASN is a central mediator of neoplastic lipogenesis and uniquely catalyzes the
Autor:
Heidi L. Weiss, Yekaterina Y. Zaytseva, B. Mark Evers, Timothy S. Heuer, George Kemble, Tianyan Gao, Piotr G. Rychahou, Eun Y. Lee
Publikováno v:
Cancer Research. 76:1010-1010
Fatty Acid Synthase (FASN), a key enzyme of de novo lipid synthesis, is upregulated in many cancers including colorectal cancer (CRC); increased FASN activity is associated with decreased survival and increased disease recurrence. Recently, a first-i
Autor:
Timothy S. Heuer, Richard Benn Abegania Ventura, Douglas Buckley, Julie Lai, George Kemble, Claudia Rubio, Joanna Waszczuk, Glenn Hammonds, Marie O' Farrell
Publikováno v:
Cancer Research. 76:4743-4743
Tumor cells have an increased dependence on FASN-synthesized palmitate compared to non-tumor cells, which obtain many of their required lipids from the extracellular milieu. Palmitate and palmitate-derived lipids comprise diverse cellular components
Publikováno v:
Molecular Cancer Research. 14:A75-A75
Dysregulated expression of FASN is a central mediator of neoplastic lipogenesis. FASN catalyzes the production of palmitate, the building block of long chain fatty acids, providing a mechanism to convert glucose and other carbon sources into lipids n
Autor:
Joanna Waszczuk, Kasia Mordec, Richard Benn Abegania Ventura, Marie O' Farrell, Timothy S. Heuer, Julie Lai, George Kemble, Douglas Buckley, Claudia Rubio
Publikováno v:
Molecular Cancer Therapeutics. 14:C175-C175
Tumor cells have an increased dependence on FASN-synthesized palmitate compared to non-tumor cells, which obtain many of their required lipids from the extracellular milieu. Palmitate and palmitate-derived lipids comprise diverse cellular components